Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥180.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥88.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥6.1bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥6.2bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥9.3bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥5.0bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.2bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.9bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥137.3bnat 2024-09-30Cons.Assets
Total assets¥117.8bnat 2024-03-31Cons.Assets
Total assets¥107.4bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥79.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥64.9bnat 2024-03-31Cons.Liabilities
Net assets / equity¥58.0bnat 2024-09-30Cons.Net assets
Net assets / equity¥52.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥50.3bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥21.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥27.3bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥21.5bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.3bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥477m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥13.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥265m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥9.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥8.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥32.432024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥131.112023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥50.82023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio39.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio44.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio46.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥64m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.2bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥7.4bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥622m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥928m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥2.7bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.5bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥124.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥686m
—segment totalsegment profit2024-04-01 → 2024-09-30¥7.9bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥63m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥173m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥801m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥142m
—segment totalrevenue2023-04-01 → 2023-09-30¥88.8bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥88.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥237m
—segment totalsegment profit2023-04-01 → 2023-09-30¥5.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 543
ItemContextValueUnit
Name major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)株式会社日本カストディ銀行(信託口)
Address major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)東京都中央区晴海一丁目8番12号
Name major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)第一三共株式会社
Address major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)東京都中央区日本橋本町三丁目5番1号
Name major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)株式会社メディパル保険サービス
Address major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)兵庫県神戸市中央区磯辺通三丁目1番7号
Name major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)中村商事株式会社
Address major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)東京都品川区
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember-
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember
Original text (Japanese)一単元(100株)未満の株式
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)クオールホールディングス株式会社
Address of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)東京都港区虎ノ門四丁目3番1号城山トラストタワー37階
Information about officers (text)FilingDateInstantText · Plus
Regulations in accordance with which consolidated financial statements have been prepared financial informationCurrentYTDDurationText · Plus
Type1 semi annual consolidated financial statements financial informationCurrentYTDDurationText · Plus
Note on independent audit financial informationCurrentYTDDurationText · Plus
Quarterly consolidated balance sheet (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of income (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of comprehensive income (text)CurrentYTDDurationText · Plus
Quarterly consolidated statement of cash flows (text)CurrentYTDDurationText · Plus
Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes additional information quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Debtors notes regarding overdraft contracts and or loan commitments (text)CurrentQuarterInstantText · Plus
Major components of selling general and administrative expenses (text)CurrentYTDDurationText · Plus
Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text)CurrentYTDDurationText · Plus
Notes regarding dividend (text)Prior1YTDDurationText · Plus
Notes when there is significant changes in amounts of equity (text)Prior1YTDDurationText · Plus
Notes regarding dividend (text)CurrentYTDDurationText · Plus
Notes when there is significant changes in amounts of equity (text)CurrentYTDDurationText · Plus
Notes segment information etc quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Footnotes regarding segment information table (text)Prior1YTDDurationText · Plus
Footnotes regarding segment information table (text)CurrentYTDDurationText · Plus
Notes business combinations quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes revenue recognition quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes per share information quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Other information consolidated financial statements etc (text)CurrentYTDDurationText · Plus
Information about company which provides guarantee to reporting company (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass